JP2009541386A5 - - Google Patents

Download PDF

Info

Publication number
JP2009541386A5
JP2009541386A5 JP2009516964A JP2009516964A JP2009541386A5 JP 2009541386 A5 JP2009541386 A5 JP 2009541386A5 JP 2009516964 A JP2009516964 A JP 2009516964A JP 2009516964 A JP2009516964 A JP 2009516964A JP 2009541386 A5 JP2009541386 A5 JP 2009541386A5
Authority
JP
Japan
Prior art keywords
alkyl
acid
alkoxy
substituted
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009516964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541386A (ja
Filing date
Publication date
Priority claimed from GBGB0612721.1A external-priority patent/GB0612721D0/en
Application filed filed Critical
Publication of JP2009541386A publication Critical patent/JP2009541386A/ja
Publication of JP2009541386A5 publication Critical patent/JP2009541386A5/ja
Pending legal-status Critical Current

Links

JP2009516964A 2006-06-27 2007-06-25 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター Pending JP2009541386A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612721.1A GB0612721D0 (en) 2006-06-27 2006-06-27 Organic compounds
PCT/EP2007/005597 WO2008000419A1 (en) 2006-06-27 2007-06-25 S1p receptor modulators for treating multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013076909A Division JP2013166761A (ja) 2006-06-27 2013-04-02 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター

Publications (2)

Publication Number Publication Date
JP2009541386A JP2009541386A (ja) 2009-11-26
JP2009541386A5 true JP2009541386A5 (https=) 2010-08-26

Family

ID=36888144

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2009516964A Pending JP2009541386A (ja) 2006-06-27 2007-06-25 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2013076909A Pending JP2013166761A (ja) 2006-06-27 2013-04-02 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2016087703A Withdrawn JP2016185957A (ja) 2006-06-27 2016-04-26 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2018021389A Withdrawn JP2018109018A (ja) 2006-06-27 2018-02-08 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2019089217A Active JP6931019B2 (ja) 2006-06-27 2019-05-09 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2020176666A Active JP7258832B2 (ja) 2006-06-27 2020-10-21 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2023061697A Pending JP2023098949A (ja) 2006-06-27 2023-04-05 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2024172795A Pending JP2025016462A (ja) 2006-06-27 2024-10-01 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2013076909A Pending JP2013166761A (ja) 2006-06-27 2013-04-02 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2016087703A Withdrawn JP2016185957A (ja) 2006-06-27 2016-04-26 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2018021389A Withdrawn JP2018109018A (ja) 2006-06-27 2018-02-08 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2019089217A Active JP6931019B2 (ja) 2006-06-27 2019-05-09 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2020176666A Active JP7258832B2 (ja) 2006-06-27 2020-10-21 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2023061697A Pending JP2023098949A (ja) 2006-06-27 2023-04-05 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JP2024172795A Pending JP2025016462A (ja) 2006-06-27 2024-10-01 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター

Country Status (20)

Country Link
US (3) US20100168078A1 (https=)
EP (4) EP2959894B1 (https=)
JP (8) JP2009541386A (https=)
KR (6) KR20090024281A (https=)
CN (2) CN101478961B (https=)
AU (7) AU2007264031C1 (https=)
BR (1) BRPI0713985A2 (https=)
CA (1) CA2653569C (https=)
DE (1) DE15177166T1 (https=)
DK (1) DK2959894T3 (https=)
ES (1) ES2887042T3 (https=)
GB (1) GB0612721D0 (https=)
HU (1) HUE059922T4 (https=)
LT (1) LT2959894T (https=)
MX (3) MX2008016133A (https=)
PL (1) PL2959894T3 (https=)
PT (1) PT2959894T (https=)
RU (1) RU2617502C2 (https=)
SI (1) SI2959894T1 (https=)
WO (1) WO2008000419A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
CA2684953C (en) * 2007-05-04 2016-08-09 Novartis Ag Use of s1p receptor modulator
JP2011525189A (ja) * 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物
KR101618906B1 (ko) * 2008-08-18 2016-05-09 노파르티스 아게 말초 신경병증의 치료를 위한 화합물
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
KR20110101159A (ko) * 2008-12-18 2011-09-15 노파르티스 아게 신규 염
JP2012512884A (ja) 2008-12-18 2012-06-07 ノバルティス アーゲー １−（４−｛１−［（ｅ）−４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシイミノ］−エチル｝−２−エチル−ベンジル）−アゼチジン−３−カルボン酸の新規の多形相
US20120115840A1 (en) * 2008-12-18 2012-05-10 Lech Ciszewski Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
MX2012006028A (es) * 2009-11-24 2012-06-19 Allergan Inc Compuestos novedosos como moduladores de receptor con utilidad terapeutica.
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
CN102120720B (zh) * 2011-01-25 2013-05-22 上海华升生物科技有限公司 盐酸芬戈莫德的合成新方法
BR112014009141A8 (pt) * 2011-10-21 2017-06-20 Novartis Ag regime de dosagem para um modulador ou agonista do receptor s1p
CN104170419B (zh) * 2012-03-23 2018-11-02 日本电气株式会社 订户服务器、监视服务器、移动终端、与之相关的方法和计算机可读介质
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
CN105611917A (zh) 2013-10-11 2016-05-25 帝国制药美国公司 局部鞘氨醇-1-磷酸酯受体激动剂制剂及其使用方法
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US20190047951A1 (en) 2016-01-04 2019-02-14 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
JP7749552B2 (ja) 2019-10-31 2025-10-06 イドルシア・ファーマシューティカルズ・リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
AU2022328858A1 (en) * 2021-08-20 2024-02-22 The Brain Protection Company PTY LTD Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB612721A (en) 1946-02-11 1948-11-17 Richard William Bailey Improvements in combustion product power plant
DE69321823T2 (de) 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ES2240868T3 (es) 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
CN1660840A (zh) 1999-03-30 2005-08-31 诺瓦提斯公司 治疗炎性疾病的酞嗪衍生物
AR025068A1 (es) 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
PT1254138E (pt) 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
DE10033541C2 (de) 2000-07-11 2003-05-15 Litef Gmbh Lichtleitfaserspule für ein faseroptisches Sagnac-Interferometer und Verfahren zu ihrer Herstellung
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
RU2199339C2 (ru) 2001-02-23 2003-02-27 Общество с ограниченной ответственностью "Биотех" Способ лечения рассеянного склероза
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
PT1505959E (pt) * 2002-05-16 2009-02-05 Novartis Ag Utilização de agentes de ligação do receptor edg em cancro
BR0311347A (pt) * 2002-05-27 2005-02-22 Novartis Ag Alcanóis bis-aromáticos
EP1575576A2 (en) 2002-09-24 2005-09-21 Novartis AG Organic compounds
KR20040048231A (ko) * 2002-12-02 2004-06-07 주식회사 두산 신생혈관생성 억제제 및 그를 포함한 암 치료용 키트
FR2848495B1 (fr) * 2002-12-12 2006-11-17 Sidel Sa Four pour chauffer au defile des ebauches de recipients en materiau thermoplastique
PE20130200A1 (es) 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
CL2004001120A1 (es) 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
EP1644367B1 (en) * 2003-05-19 2015-10-14 Novartis AG Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
CA2567686A1 (en) * 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
CN101102791B (zh) * 2004-11-18 2011-12-14 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
KR20070085465A (ko) * 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
US20060134111A1 (en) * 2004-12-17 2006-06-22 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
RU2278687C1 (ru) 2005-06-16 2006-06-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" (ГОУ ВПО БГМУ РОСЗДРАВА РОССИИ) Способ лечения ремиттирующего рассеянного склероза
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP2323679A4 (en) 2008-07-25 2012-08-22 Univ Colorado CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION
GB2527550B (en) 2014-06-25 2016-09-21 Cook Medical Technologies Llc Implantable medical device with lumen constriction

Similar Documents

Publication Publication Date Title
JP2009541386A5 (https=)
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
JP2014515013A5 (https=)
EP2592070A3 (en) Tetrazole-substituted arylamides
JP2009534471A5 (https=)
WO2009087212A3 (en) Pyridine derivatives
EA201001129A1 (ru) Пиримидины в качестве ингибиторов киназы
CY1112826T1 (el) [4-(6-αλογονο-7-υποκατεστημενες-2,4-διοξο-1,4-διϋδρο-2η-κιναζολιν-3-υλ)-φαινυλ]-5-χλωρο-θειοφαιν-2-υλ-σουλφονυλουριες και μορφες και μεθοδοι που σχετιζονται με αυτες
NO20054206L (no) Bifenylderivater
JP2017528503A5 (https=)
JP2011512412A5 (https=)
JP2010526801A5 (https=)
JP2007523051A5 (https=)
JP2012530758A5 (https=)
WO2007127196A3 (en) DIALKYLPHENYL COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP2010520214A5 (https=)
JP2005522432A5 (https=)
NO20076481L (no) Benzimidazol-karboksamidforbindelser som 5-HT4 receptorantagonister
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
EA201001645A1 (ru) Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
JP2017509611A5 (https=)
CL2007002349A1 (es) Compuestos derivados de pirazolo[3,4-b]piridina; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de una enfermedad inflamatoria y/o alergica, tal como epoc, asma y rinitis.
JP2009501745A5 (https=)
JP2012511558A5 (https=)
WO2009145816A3 (en) Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents